Raushan Bayaliyeva

Raushan Bayaliyeva


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MKMoldir Koilybaeva
Moldir Koilybaeva
ZSZhanserik Shynykul
Zhanserik Shynykul
GUGulbaram Ustenova
Gulbaram Ustenova
KWKrzysztof Waleron
Krzysztof Waleron
JJJoanna Jonca
Joanna Jonca
ZAZhazira Alibayeva
Zhazira Alibayeva
Bacillus species produce different classes of antimicrobial and antioxidant substances: peptides or proteins with different structural compositions and molecular masses and a broad range of volatile organic compounds (VOCs), some of which may serve as biomarkers for microorganism identification. The aim of this study is the identification of biologically active compounds synthesized by five Bacillus species using gas chromatography coupled to mass spectrometry (GC–MS). The current study profoundly enhances the knowledge of antibacterial and antioxidant metabolites ensuring the unambiguous identification of VOCs produced by some Bacillus species, which were isolated from vegetable samples of potato, carrot, and tomato. Phylogenetic and biochemical studies were used to identify the bacterial isolates after culturing. Phylogenetic analysis proved that five bacterial isolates BSS12, BSS13, BSS16, BSS21, and BSS25 showed 99% nucleotide sequence similarities with Bacillus safensis AS-08, Bacillus cereus WAB2133, Bacillus acidiproducens NiuFun, Bacillus toyonesis FORT 102, and Bacillus thuringiensis F3, respectively. The crude extract was prepared from bacterial isolates to assess the antibiotic resistance potency and the antimicrobial potential against various targeted multidrug-resistant strains, including yeast strains such as Candida albicans, Candida krusei, and bacterial strains of Enterococcus hirae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus group B, Streptococcus mutans, Shigella sonnei, Salmonella enteritidis, Serratia marcescens, Pseudomonas aeruginosa, and Proteus vulgaris. GC–MS analysis of bacterial strains found that VOCs from Bacillus species come in a variety of chemical forms, such as ketones, alcohols, terpenoids, alkenes, etc. Overall, 69 volatile organic compounds were identified from five Bacillus species, and all five were found to share different chemical classes of volatile organic components, which have a variety of pharmacological applications. However, eight antibacterial compounds with different concentrations were commonly found in all five species: acetoin, acetic acid, butanoic acid, 2-methyl-, oxime-, methoxy-phenyl, phenol, 1,2-benzenedicarboxylic acid, bis(2-methylpropyl) ester, nonanoic acid, and hexadecanoic acid, methyl. The present study has demonstrated that bacterial isolates BSS25, BSS21, and BSS16 display potent inhibitory effects against Candida albicans, while BSS25, BSS21, and BSS13 exhibit the ability to restrain the growth and activity of Candida krusei. Notably, BSS25 and BSS21 are the only isolates that demonstrate substantial inhibitory activity against Klebsiella aerogenes. This disparity in inhibitory effects could be attributed to the higher concentrations of acetoin in BSS25 and BSS21, whereas BSS16 and BSS13 have relatively elevated levels of butanoic acid, 2-methyl-. Certainly, the presence of acetoin and butanoic acid, 2-methyl-, contributes to the enhanced antibacterial potential of these bacterial strains, in conjunction with other organic volatile compounds and peptides, among other factors. The biology and physiology of Bacillus can be better understood using these results, which can also be used to create novel biotechnological procedures and applications. Moreover, because of its exceptional ability to synthesize and produce a variety of different antibacterial compounds, Bacillus species can serve as natural and universal carriers for antibiotic compounds in the form of probiotic cultures and strains to fight different pathogens, including mycobacteria.

11 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MKMoldir Koilybaeva
Moldir Koilybaeva
ZSZhanserik Shynykul
Zhanserik Shynykul
GUGulbaram Ustenova
Gulbaram Ustenova
KWKrzysztof Waleron
Krzysztof Waleron
KMKamilya Mustafina
Kamilya Mustafina
ZAZhazira Alibayeva
Zhazira Alibayeva
Bacillus species produce different classes of antimicrobial and antioxidant substances: peptides or proteins with different structural composition and molecular mass and a broad range of volatile organic compounds (VOCs), some of which may serve as biomarkers for microorganism identification. The aim of this study is the identification of biologically active compounds synthesized by five Bacillus species using gas chromatography coupled to mass spectrometry (GC–MS). The current study profoundly enhances the knowledge of antibacterial and antioxidant metabolites ensuring the unambiguous identification of VOCs produced by some Bacillus species, which were isolated from vegetable samples of potato, carrot, and tomato. Phylogenetic and biochemical studies were used to identify the bacterial isolates after culturing. Phylogenetic analysis proved that five bacterial isolates BSS12, BSS13, BSS16, BSS21, and BSS25 showed 99% nucleotide sequence similarities with Bacillus safensis AS-08, Bacillus cereus WAB2133, and Bacillus acidiproducens NiuFun, Bacillus toyonesis FORT 102 and Bacillus thuringiensis F3, respectively. The crude extract was prepared from bacterial isolates to assess the antibiotic resistance potency and the antimicrobial potential against various targeted multidrug-resistant strains, including Candida albicans, Candida krusei, Enterococcus hirae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus group B, Streptococcus mutans, Shigella sonnei, Salmonella enteritidis, Serratia marcescens, Pseudomonas aeruginosa, and Proteus vulgaris. GC–MS analysis of bacterial strains found that VOCs from Bacillus species come in a variety of chemical forms, such as ketones, alcohols, terpenoids, alkenes, etc. Overall, 69 volatile organic compounds were identified from five Bacillus species, and all five were found to share different chemical classes of volatile organic components, which have a variety of pharmacological applications. However, 8 antibacterial compounds with different concentrations were commonly found in all five species: acetoin, acetic acid, butanoic acid, 2-methyl-, oxime-, methoxy-phenyl, phenol, 1,2-benzenedicarboxylic acid, bis(2-methylpropyl) ester, nonanoic acid, and hexadecanoic acid, methyl. The biology and physiology of Bacillus can be better understood using these results, which can also be used to create novel biotechnological procedures and applications. Moreover, because of its exceptional ability to synthesize and produce a variety of different antibacterial compounds, Bacillus species can serve as natural and universal carriers for antibiotic compounds in the form of probiotic cultures and strains to fight different pathogens, including mycobacteria.

30 June 2026 in Central Asian Journal of Medical Hypotheses and Ethics
Verified
Journal Article
Open access
RBRaushan Bayaliyeva
Raushan Bayaliyeva
EKErmagambet Kuatbaev
Ermagambet Kuatbaev
ARArgul Razbekova
Argul Razbekova
AKAinur Kumar
Ainur Kumar
BABakytzhan Akylbek
Bakytzhan Akylbek
DNDilara Nurbaeva
Dilara Nurbaeva
Background: Acute myocardial infarction (AMI) remains a major cause of mortality worldwide, with outcomes strongly influenced by healthcare system organization and timely access to reperfusion therapy. Evidence from Central Asia, including Kazakhstan, remains limited, particularly regarding real-world hospital-based outcomes. Objective: To assess clinical outcomes and temporal trends in the management of AMI in a tertiary cardiac center in Almaty, Kazakhstan. Methods: A retrospective observational cohort study was conducted at the City Cardiology Center in Almaty, including all adult patients with AMI admitted between 2023 and 2025. Data were obtained from hospital databases and institutional reports. Primary outcomes included in-hospital mortality, early (24-hour) mortality, and 30-day mortality. Secondary outcomes included procedural volumes and system performance indicators. Temporal trends were analyzed across study years. Results: In-hospital mortality remained stable (1.8% in 2023–2024 vs. 1.9% in 2025), as did AMI-specific mortality (6.0% in 2024 vs. 6.1% in 2025). However, significant improvements were observed in short-term outcomes. Early mortality decreased from 69 to 60 cases (–13.0%), while 30-day mortality declined from 176 to 163 cases (–7.4%). Post-discharge mortality also decreased from 57 to 48 cases (–15.8%). Procedural volumes showed mixed trends: PCI and stenting volumes decreased, while coronary angiography volumes remained stable or slightly increased. At the same time, system performance indicators improved substantially: the proportion of patients seeking care within 60 minutes increased from 55.2% to 89.0%, and the proportion of patients undergoing PCI within 60 minutes of arrival increased from 57.2% to 70.4%. Conclusion: Improvements in healthcare system performance, particularly reduced treatment delays and optimized care pathways, were associated with better short-term outcomes in AMI patients. These findings highlight the importance of system-level interventions and provide valuable evidence for strengthening cardiovascular care in Kazakhstan and other Central Asian countries.